

Thyroid Disorders

Swathi Badarla*

Department of Pharmaceutical Analysis and Quality Assurance, Montessori College of Pharmacy,
Mylavaram, Vijayawada, Andhra Pradesh, India

Review Article

Received: 24/11/2016
Revised: 29/11/2016
Accepted: 02/12/2016

*For Correspondence

Department of Pharmaceutical
Analysis and Quality Assurance,
Montessori College of Pharmacy,
Mylavaram, Vijayawada, India,
Tel: 91+ 9848258639.

E-mail:

swathipharmacy52gmail.com

Keywords: Neonatal gland
disease, Newborn, Blood spot,
thyroid hormone, CH screening.

ABSTRACT

Decreased level of thyroid hormone formed by pituitary is thought as hypothyroid disease and increased level of thyroid formed by pituitary is thought as hyperthyroid disease. Poorly treated or untreated maternal over thyroid sickness might have an effect on maternity outcome. The complicate health problems throughout maternity and baby area unit foetal and baby hypo or thyrotoxicosis and baby central glandular disease. Appropriate identification and treatment of hypothyroid and hyperthyroid disease throughout maternity time are of most important. Because as a result of thyroid disorder there will be many worse effects on both mother and child. Propylthiouracil and Methimazole can be considered as a drug which can treat thyroid disorder at the time of pregnancy and lactating period.

INTRODUCTION

Hypothyroidism conjointly referred to as hypoactive thyroid or low thyroid. It happens unremarkably in the system in which the thyroid doesn't manufacture enough hormones. A number of its symptoms are less resistance power to consume cold, a sense of weariness, abdominal discomfort, depression, and heavy weight. Generally there could also be swelling from the part of the neck because of disease. Untreated hypothyroidism throughout maternity will result in delays in growth and intellectual development within the baby that is the main adverse effect of hypothyroidism [1-24].

Mostly the usual cause for hypothyroidism is just too very little iodine within the diet [25-37].

Hyperthyroidism is additionally referred to as overactive thyroid or high thyroid. It conjointly happens unremarkably within the system that gives excessive production of hormone by the thyroid. Adenosis is the condition that happens because of excessive hormone produced in pituitary. Thyroid disorder symptoms are different from one person to other person and should embrace illnature, joint pains, sleep disorders, heart problems, and sensitivity to heat, vomiting, thyroid expansion, and loss of weight. Hyperthyroidism is a condition which can result worse symptoms like confusion and a hot temperature and sometimes ends up in death. The alternative is gland disease, once the thyroid doesn't create enough hormones [38-51].

Mostly the usual cause for hyperthyroidism are Graves' disease, nodular disease, virulent benign tumor, swelling of the thyroid, consumption an excessive amount of iodine, and an excessive amount of artificial hormone. A less common cause may be a pituitary benign tumor [52-68].

Tests for thyroid disorders

Thyroid stimulating hormone test

In this test, the level of Thyroid Stimulating Hormone takes in to consideration. Decreased level of T3 and T4 thyroid hormone results into hypothyroidism. Pituitary gland stimulates the discharge of those hormones into the blood through Thyroid Stimulating Hormone (TSH); therefore hypothyroidism disorder is outlined strictly primarily based upon your levels of Thyroid Stimulating Hormone (TSH).

Increase level of T3 and T4 thyroid hormone results into hyperthyroidism. Thus in diagnosis of thyroid disorder Thyroid Stimulating Hormone plays a vital role. If the value of Thyroid Stimulating Hormone is normal but the symptoms are still present, then go to the other tests [69-87].

T4 Test

If the value of Thyroid Stimulating Hormone is normal but the symptoms are still present, then T4 test should be done. The level of T4 thyroid hormone which is present in tissues and blood stream should be measured in this test. If the level of T4 thyroid hormone is less, then consider as hypothyroidism. Actually in hypothyroidism there will be high level of Thyroid Stimulating Hormone and low level of T4 thyroid hormone. But in hyperthyroidism, there will be high level of Thyroid Stimulating Hormone and high level of T4 thyroid hormone [71-88].

DISCUSSION

As a result, thyroid disorders in pregnant ladies will adversely have an effect on their children's sequent performance on psychological behaviour. In Some situations symptoms of thyroid disorder may be less in pregnant lady. The presence of high humor concentrations of pismire thyroid oxidase antibodies in seventy seven percentage of {the girls|the ladies} with gland disease shows the persistent response rubor was the foremost frequent reason behind gland disease in these pregnant ladies. Treating of maternal thyroid disease throughout maternity seems to be useful for the kid, even once treatment is insufficient as determined by measurements of thyrotrophic.

In general pregnancy, there's a physical increase in free tetraiodothyronine and a decrease in thyrotrophic and these changes are largest at the time the human sac gonadotropic hormone concentration peaks (approximately ten to twelve weeks of gestation). In our subjects, we tend to failed to observe this increase. Rather, there was a peak within the thyrotrophic concentration at regarding eight to ten weeks of gestation, amid a downward trend within the free tetraiodothyronine index. These results counsel that a very important role of the human sac gonadotropin-thyroid axis in healthy ladies is to extend the hormone pool throughout the primary trimester [89-98].

CONCLUSION

During pregnancy special considerations should be needed to manage the thyroidism disorders. If the special considerations are taken then the worse effects on the pregnant lady, child and infants can be avoided. Iodine deficiency is one of the reason that effect mother and fetal and infants. Iodine helps to develop the brain of fetal during pregnancy time. So Iodine should be taken sufficiently by the pregnant women as it helps to develop the brain of fetal during pregnancy time. As a result Iodine plays a vital role in thyroid disorder. Thus Iodine deficiency results into hypo and hyperthyroidism.

REFERENCES

1. Waring JF, et al. Gene Expression Changes Related to Synaptic Deficits in the Tg2576 Mouse Model of Alzheimer's Disease. *J Drug Metab Toxicol.* 2012;3:115.
2. Xin-Mei C, et al. New Progress on the Pharmacological and Pharmacokinetical Study of Ginsenoside Rg3. *J Drug Metabol Toxicol.* 2012;3:114.
3. Santosh Kumar. Role of Cytochrome P450 Systems in Substance of Abuse Mediated HIV-1 Pathogenesis and NeuroAIDS. *J Drug Metab Toxicol.* 2012;3:102.
4. Abraham G. Unpredictable Systemic Risks to Topical Drugs. *J Drug Metab Toxicol.* 2014;5:122.
5. Hou SM, et al. Susceptibility of Human Lymphocytes to 2-Nitrofluorene-Induced Gene Mutation is Strongly Dependent on Metabolic Genotypes. *J Drug Metab Toxicol.* 2012;3:116.
6. Ansari R. Defining the Role of Single Nucleotide Polymorphic (SNP) in Drug Development and Toxicity. *J Drug Metab Toxicol.* 2012;3:103.
7. Ansari R. Editorial. *J Drug Metab Toxicol.* 2012;3:104.
8. Colalto C. Unpredictable Adverse Reactions to Herbal Products. *J Drug Metab Toxicol.* 2012;3:105.
9. Johnson DE. Predicting Drug Safety: Next Generation Solutions. *J Drug Metab Toxicol.* 2012;3:106.
10. Piero NM, et al. In Vivo Antidiabetic Activity and Safety In Rats of Cissampelos pareira Traditionally Used In The Management of Diabetes Mellitus In Embu County, Kenya. *J Drug Metab Toxicol.* 2015;6:184.
11. Birandra KS, Mason RP Is Metabolic Activation of Topoisomerase II Poisons Important In The Mechanism Of Cytotoxicity?. *J Drug Metab Toxicol.* 2015;6:186.
12. Seçkin HY, et al. A Clinical Experience: A Cutaneous Leishmaniasis Case with Spontan Abortus Following To Meglumine Antimoniate Therapy. *J Drug Metab Toxicol.* 2015;6:183.
13. Zhang AH, et al. Potential Applications and Development of Cell Metabolomics in Natural Products. *J Drug Metab Toxicol.* 2014;5:163.

14. McCormick MA, et al. Review of Marijuana Use in the Adolescent Population and Implications of its Legalization in the United States. *J Drug Metab Toxicol.* 2014;5:165.
15. Kumar S. Plasma Exosomes and Drug Metabolic Cytochrome P450 Enzymes. *J Drug Metab Toxicol.* 2015;6:124.
16. Kumar V, et al. Nanostructures for Drug Delivery. *J Drug Metab Toxicol.* 2015;6:125.
17. Shindoh C, et al. Effects of Long-Acting β 2-Agonist and Corticosteroid Inhalation on Diaphragm Muscle in Mice. *J Drug Metab Toxicol.* 2015;5:176.
18. Charfi R, et al. PRES Induced By Cyclosporin with Normal Blood Concentrations in a Bone Marrow Recipient. *J Drug Metab Toxicol.* 2015;6:178.
19. Saganuwan SA. Arithmetic-Geometric-Harmonic (AGH) Method of Rough Estimation of Median Lethal Dose (Ld50) Using Up- and - Down Procedure. *J Drug Metab Toxicol.* 2015;6:180.
20. Huang H, et al. Ozone-Oxidation Products of Ibuprofen and Toxicity Analysis in Simulated Drinking Water. *J Drug Metab Toxicol.* 2015;6:181.
21. Uma KK, et al. A Review of the Biochemical, Hematological and Histological Modulations in Acetaminophen Induced Hepatotoxicity and the Potential of *Urtica Dioica* in the Regeneration of the Liver. *J Drug Metab Toxicol.* 2015;6:182.
22. Chen Q. Vitamin C in Cancer Treatment: Where Pharmacokinetics Speaks. *J Drug Metab Toxicol.* 2012;3:107.
23. Yang L, et al. Sex Differences in the Expression of Drug-Metabolizing and Transporter Genes in Human Liver. *J Drug Metab Toxicol.* 2012;3:119.
24. Sari A, et al. Determination of MDA Levels in the Plant (Some *Salvia L. Taxa* Growing in Turkey). *J Drug Metab Toxicol.* 2012;3:117.
25. Akande IS. Biochemical Evaluation of Some Locally Prepared Herbal Remedies (Agbo) Currently On High Demand in Lagos Metropolis, Nigeria. *J Drug Metab Toxicol.* 2012;3:118.
26. Adebayo AJ, et al. Influence of Isoniazid Treatment on Microsomal Lipid peroxidation and Antioxidant Defense Systems of Rats. *J Drug Metab Toxicol.* 2012;3:120.
27. Nanjwade BK, et al. Development and Evaluation of Gastroretentive Floating Tablets of Glipizide Based on Effervescent Technology. *J Drug Metab Toxicol.* 2012;3:121.
28. Pathak A. Role of Zinc on Antioxidative Enzymes and Lipid Peroxidation in Brain of Diabetic Rats. *J Drug Metab Toxicol.* 2012;3:122.
29. Stengel PW. Insight into Pulmonary Gas Trapping as an Index of Airway Responses in Small Laboratory Animals. *J Drug Metab Toxicol.* 2014;5:166.
30. Kalla RMN, et al. Synthesis of 14-aryl/ alkyl-14H-dibenzo [a,j] Xanthenes and Nitriles Catalyzed by $\text{KHSO}_4\text{-SiO}_2$ Under Ultra-sonication and Solvent-free Conditions. *J Drug Metab Toxicol.* 2014;5:167.
31. Sinha BK, et al. Biotransformation of Hydrazine Derivatives in the Mechanism of Toxicity. *J Drug Metab Toxicol.* 2014;5:168.
32. Amin AR. The Metabolomics of Nitric Oxide and Reactive Nitrogen Species in Immune Editing Tumor Milieu: Influence of Nitric Oxide-Modulating Therapies. *J Drug Metab Toxicol.* 2012;8:002.
33. Ding WX. Autophagy in Toxicology: Defense against Xenobiotics. *J Drug Metab Toxicol.* 2012;3:108.
34. Meier-Davis SR, et al. Absorption, Distribution and Excretion Pattern of Oral and Transdermal Donepezil Hydrochloride after Single and Repeated Administration to the Rat. *J Drug Metab Toxicol.* 2012;3:123.
35. Ozok N, et al. Effects of Subacute and Subchronic Treatment of Synthetic Plant Growth Regulators on Liver Damage Serum Biomarkers Tissue Antioxidant Defense Systems and Lipid Peroxidation in Rats. *J Drug Metab Toxicol.* 2012;3:124.
36. Gaies E, et al. Methotrexate Side Effects: Review Article. *J Drug Metab Toxicol.* 2012;3:125.
37. Singh JK, et al. Comparative in-vitro Intrinsic Clearance of Imipramine in Multiple Species Liver Microsomes: Human, Rat, Mouse and Dog. *J Drug Metab Toxicol.* 2012;3:126.
38. Adebayo AJ, et al. Microsomal Lipid Peroxidation, Antioxidant Enzyme Activities in Brain of Male Rats during Long-Term Exposure to Isoniazid. *J Drug Metab Toxicol.* 2012;3:127.
39. Taguchi K, et al. A Fourteen-Day Observation and Pharmacokinetic Evaluation after a Massive Intravenous Infusion of Hemoglobin-Vesicles (Artificial Oxygen Carriers) in *Cynomolgus* Monkeys. *J Drug Metab Toxicol.* 2012;3:128.
40. Meier-Davis SR, et al. Comparison of Metabolism of Donepezil in Rat, Mini-Pig and Human, Following Oral and Transdermal Administration, and in an in vitro Model of Human Epidermis. *J Drug Metab Toxicol.* 2012;3:129.
41. Bordoloi R, et al. Microbial Toxin Production: Opportunists and True Pathogens. *J Drug Metab Toxicol.* 2014;5:123.
42. Sherkhane AS. Identification of MHC Class, Transports Antigenic Peptides from *Naja melanoleuca* Long Neurotoxin 1. *J Drug Metab Toxicol.* 2014;5:169.
43. Nahata MC. Impact of Pharmacokinetics on Dosage Requirements and Medication Safety in Pediatric Patients. *J Drug Metab Toxicol.* 2012;3:109.
44. Preissner S. Drug Interactions Involving the Cytochrome P450 Enzymes: Analysis of Common Combinations of Antibiotics and Pain Relieving Drugs. *J Drug Metab Toxicol.* 2012;3:131.

45. Toffoli G. Pharmacogenetics as Innovative Approach for Phase I Clinical Studies in Cancer Patients. *J Drug Metab Toxicol.* 2012;3:110.
46. Dwivedi VK, et al. Prevention of Cadmium Toxicity by Ceftriaxone plus Sulbactam with VRP1034 in Rats. *J Drug Metab Toxicol.* 2012;3:130.
47. Sun J. Metabolomics in Drug-induced Toxicity and Drug Metabolism. *J Drug Metab Toxicol.* 2012;3:111.
48. Bluemel J. Toxicity Testing in the 21st Century: Challenges and Perspectives. *J Drug Metab Toxicol.* 2012;3:112.
49. Iyanda AA. Assessment of Lipid Peroxidation and Activities of Antioxidant Enzymes in Phosphide- Powder Residue Exposed Rats. *J Drug Metab Toxicol.* 2012;3:132.
50. Soloway AH. Potential Carcinogens from Steroid Hormones and Diethyl Stilbesterol (DES): Chemical Relationships between Breast, Ovarian and Prostate Cancers. *J Drug Metab Toxicol.* 2014;5:170.
51. Landry KK. 17-Hydroxemestane: A Potent Inhibitor of CYP19 (Aromatase) and Substrate of CYP3A. *J Drug Metab Toxicol.* 2014;5:171.
52. Maso S, et al. Testosterone and Estradiol Affect Renal Oxidative Metabolism and Glutathione Pathway of Wistar Rats. *J Drug Metab Toxicol.* (2011);7:001.
53. Wang C, et al. Nonhuman Primate Models and Developmental Neuronal Toxicity. *J Drug Metab Toxicol.* 2012;3:113.
54. Johnson DE. Estimating Human Cancer Risk from Rodent Carcinogenicity Studies: The Changing Paradigm for Pharmaceuticals. *J Drug Metab Toxicol.* 2012;3:114.
55. Singh TB, et al. Induced Acetamidiprid Toxicity in Mice: A Review. *J Drug Metab Toxicol.* 2012;3:115.
56. Singh TB, et al. Acetamidiprid Induces Toxicity in Mice under Experimental Conditions with Prominent Effect on the Hematobiochemical Parameters. *J Drug Metab Toxicol.* 2012;3:134.
57. Sharma S. Hepatic Metabolism of 17 α -hydroxyprogesterone Caproate in Mice, Rats, Dogs, Pigs, Rabbits and Baboons: A Comparison with Human Liver Microsomes and Human Hepatocytes. *J Drug Metab Toxicol.* 2012;3:135.
58. Cavallaro S. Transcriptional Mechanisms Underlying Apoptosis in Cerebellar Granule Neurons. *J Drug Metab Toxicol.* 2012;3:136.
59. Arindkar S. The Effect of Fasting on Haematology Serum Biochemistry Parameters on STZ Induced CD1 Mice and Diabetic db/db Mice. *J Drug Metab Toxicol.* 2012;3:137.
60. Khargharia S, et al. Disposition Kinetic of Amoxicillin in Healthy and Nephropathic Goats with Immunological and Residual Level in Blood and Tissues. *J Drug Metab Toxicol.* 2012;5:003.
61. Lowry JA, et al. Lead and its Effects on Cytochromes P450. *J Drug Metab Toxicol.* 2012;5:004.
62. Kurşat M, et al. Some Biological Contents and Radical Scavenging Activities of Five Artemisia L. Species Growing in Turkey. *J Drug Metab Toxicol.* 2014;5:172.
63. Sakai C, et al. Species Differences in the Pharmacokinetic Parameters of Cytochrome P450 Probe Substrates between Experimental Animals, such as Mice, Rats, Dogs, Monkeys, and Microminipigs, and Humans. *J Drug Metab Toxicol.* 2014;5:173.
64. Ouafy TE, et al. Electrochemical Detection of p-Chloroaniline at Clay Modified Carbon Paste Electrode: Application in Tap Water. *J Drug Metab Toxicol.* 2015;5:174.
65. Dwivedi V, et al. Efficacy Study of Livartha against Paracetamol Induced Hepatotoxicity in Adult Sprague Dawley Rats. *J Drug Metab Toxicol.* 2015;5:175.
66. Grundmann O. The Gut Microbiome and Pre-systemic Metabolism: Current State and Evolving Research. *J Drug Metab Toxicol.* 2010;1:104.
67. Uyemura K, et al. Metabolism and Toxicity of High Doses of Cyclo (his-pro) Plus Zinc in Healthy Human Subjects. *J Drug Metab Toxicol.* 2010;1:105.
68. Essawy AE, et al. Hepatotoxicity Induced by Antifungal Drug Fluconazole in the Toads (*Bufo Regularis*). *J Drug Metab Toxicol.* 2010;1:106.
69. Burrow GN. Editorial: thyroid status in normal pregnancy. *J Clin Endocrinol Metab.* 1990;71:274-275.
70. Glinoe D. The Regulation of Thyroid Function in Pregnancy: Pathways of Endocrine Adaptation from Physiology to Pathology. *Endocr Rev* 1997;18:404-33.
71. De Groot L, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2012;97:2543-2565.
72. Delange F. Iodine requirements during pregnancy, lactation and the neonatal period and indicators of optimal iodine nutrition. *Public Health Nutr.* 2007;10:1571-1580.
73. Abalovich M. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. *Thyroid.* 2011;21:1081-1125.
74. Poppe K, et al. The role of thyroid autoimmunity in fertility and pregnancy. *Nat Clin Pract Endocrinol Metab.* 2008;4:394-405.
75. Bartalena L, et al. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. *J Endocrinol Invest.* 2001;24:116-130.

76. Mandel SJ. The use of antithyroid drugs in pregnancy and lactation. *J Clin Endocrinol Metab.* 2001;86:2354-2359.
77. Hendrick V. Hormonal changes in the postpartum and implications for postpartum depression. *Psychosomatics.* 1998;39:93-101.
78. Mitchell ML. Iodine supplementation for pregnancy and lactation-United States and Canada: recommendations of the American Thyroid Association. *Thyroid.* 2006;16:949-951.
79. Schnatz PF, et al. Primary hyperparathyroidism in pregnancy: evidence-based management. *Obstet Gynecol Surv.* 2002;57:365-376.
80. Oppenheimer JH. Thyroid hormone action at the cellular level. *Science.* 1979;203:971-979.
81. Rashid M. Obstetric management of thyroid disease. *Obstet Gynecol Surv.* 2007;62:680-688.
82. Moosa M, et al. Outcome of differentiated thyroid cancer diagnosed in pregnant women. *J Clin Endocrinol Metab.* 1997;82:2862-2866.
83. Butte NF, et al. Leptin in human reproduction: serum leptin levels in pregnant and lactating women. *J Clin Endocrinol Metab.* 1997;82:585-589.
84. Chattaway JM, et al. Propylthiouracil versus methimazole in treatment of Graves' disease during pregnancy. *Ann Pharmacother.* 2007;41:1018-1022.
85. Joshi JV, et al. Menstrual irregularities and lactation failure may precede thyroid dysfunction or goitre. *J Postgrad Med.* 1993;39:137-141.
86. Galofre JC, et al. Autoimmune thyroid disease in pregnancy: a review. *J Womens Health.* 2009;18:1847-1856.
87. Casey BM, et al. Perinatal significance of isolated maternal hypothyroxinemia identified in the first half of pregnancy. *Obstet Gynecol.* 2007;109:1129-1135.
88. Brent GA. Diagnosing thyroid dysfunction in pregnant women: Is case finding enough? *J Clin Endocrinol Metab.* 2007;92: 39-41.
89. Negro R, et al. The influence of selenium supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. *J Clin Endocrinol Metab.* 2007;92:1263-1268.
90. Cooper DS, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid.* 2009;19:1167-1214.
91. Gilbert RM, et al. Assessment of thyroid function during pregnancy: first-trimester reference intervals derived from Western Australian women. *Med J Aust.* 2008;189:250-253.
92. Fitzpatrick DL, et al. Diagnosis and management of thyroid disease in pregnancy. *Obstet Gynecol Clin North Am.* 2010;37:173-193.
93. Berbel P1, et al. Iodine supplementation during pregnancy: a public health challenge. *Trends Endocrinol Metab.* 2007;18:338-343.
94. Palinski W, et al. The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. *FASEB J.* 2002;16:1348-1360.
95. Clementi M, et al. Treatment of hyperthyroidism in pregnancy and birth defects. *J Clin Endocrinol Metab.* 2010;95:337-341.
96. Lazarus J, et al. European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children. *Eur Thyroid J.* 2014;3: 76-94.
97. Rebagliato, et al. Iodine intake and maternal thyroid function during pregnancy. *Epidemiology.* 2010;21:62-9.
98. Alvarez-Pedrerol M. Iodine levels and thyroid hormones in healthy pregnant women and birth weight of their offspring. *Eur J Endocrinol.* 2009;160:423-429.